Pembroke Management LTD grew its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 24.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,908,345 shares of the company's stock after buying an additional 372,619 shares during the quarter. Cellebrite DI accounts for 4.2% of Pembroke Management LTD's investment portfolio, making the stock its 4th biggest position. Pembroke Management LTD owned 0.93% of Cellebrite DI worth $32,137,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in the stock. Sei Investments Co. increased its holdings in shares of Cellebrite DI by 44.7% in the first quarter. Sei Investments Co. now owns 121,166 shares of the company's stock worth $1,343,000 after buying an additional 37,408 shares during the period. Capstone Investment Advisors LLC purchased a new stake in shares of Cellebrite DI during the first quarter valued at approximately $870,000. Inspire Investing LLC bought a new position in shares of Cellebrite DI in the first quarter worth approximately $862,000. Scalar Gauge Management LLC boosted its stake in shares of Cellebrite DI by 15.2% during the 2nd quarter. Scalar Gauge Management LLC now owns 453,554 shares of the company's stock valued at $5,420,000 after purchasing an additional 60,000 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Cellebrite DI by 26.8% in the first quarter. Acadian Asset Management LLC now owns 2,896,497 shares of the company's stock worth $32,062,000 after buying an additional 612,787 shares in the last quarter. 45.88% of the stock is owned by institutional investors.
Analysts Set New Price Targets
CLBT has been the topic of a number of research analyst reports. Lake Street Capital upped their target price on Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Needham & Company LLC boosted their target price on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 16th. TD Cowen raised their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $14.00 to $15.00 and gave the company an "overweight" rating in a report on Wednesday, August 14th. Finally, Craig Hallum increased their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $18.57.
Check Out Our Latest Report on Cellebrite DI
Cellebrite DI Trading Up 2.1 %
NASDAQ CLBT traded up $0.38 on Friday, hitting $18.53. 1,159,914 shares of the company traded hands, compared to its average volume of 1,165,664. The business's 50 day moving average price is $17.44 and its 200-day moving average price is $14.05. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of -34.96, a P/E/G ratio of 2.50 and a beta of 1.50. Cellebrite DI Ltd. has a 52-week low of $6.85 and a 52-week high of $18.75.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $91.94 million. During the same period last year, the firm earned $0.05 EPS. The company's revenue was up 24.8% on a year-over-year basis. As a group, sell-side analysts predict that Cellebrite DI Ltd. will post 0.31 earnings per share for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
